Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 24Paclitaxel 7Docetaxel 7Cyclophosphamide 7Carboplatin 7fludarabine 6Taxes 6Nivolumab 6Trastuzumab 5Magnetic Resonance Spectroscopy 5atezolizumab 4Specimen Handling 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Gemcitabine 4Fluorouracil 4Cisplatin 4tisotumab vedotin 3fludarabine phosphate 3Radiation 3Oxaliplatin 3Leucovorin 3Irinotecan 3Ipilimumab 3Gene Expression Profiling 3Drug Therapy 3Counseling 3Albumin-Bound Paclitaxel 3zimberelimab 2ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × seribantumab × Gynecologic × Clear all
NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡